Tiziana Life Sciences’ Intranasal Foralumab MS Study Published in Leading Neurology Journal
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On January 20, 2026, Tiziana Life Sciences announced that results from its open-label clinical study of intranasal foralumab in patients with non-active secondary progressive multiple sclerosis have been peer-reviewed and published in Neurology Neuroimmunology & Neuroinflammation, a journal of the American Academy of Neurology. The study, which previously reported positive data on May 6, 2025, is the first to combine TSPO-PET imaging, proteomics and clinical assessments in this patient population, showing no serious treatment-related adverse events, stabilization or improvement in disability scores, reduced fatigue in most patients, absence of new MRI lesions, and significant reductions in microglial activation alongside biomarker evidence of increased regulatory T cells and TGFβ expression. Investigators and company leaders framed the publication as a major external validation of intranasal foralumab’s differentiated mechanism of modulating CNS inflammation without broad systemic immunosuppression, strengthening Tiziana’s position in the multiple sclerosis treatment landscape as it progresses an ongoing randomized, double-blind, placebo-controlled Phase 2 trial in non-active secondary progressive MS, with top-line data expected in the first half of 2026.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough immunotherapies using alternative drug delivery technologies, particularly intranasal administration. Its lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development and is being advanced primarily for neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis, with a broader pipeline enabled by its patented delivery platform.
Average Trading Volume: 306,387
Technical Sentiment Signal: Buy
Current Market Cap: $199.7M
Learn more about TLSA stock on TipRanks’ Stock Analysis page.
